Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FH-006 + adebrelimab + apatinib
- Development stage
- Unknown
- Lead developer
- Hengrui Therapeutics
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
FH-006 + adebrelimab + apatinib is an investigational combination therapy developed by Jiangsu Hengrui Medicine for the treatment of non-small cell lung cancer (NSCLC). The regimen integrates three distinct therapeutic approaches: FH-006, a recombinant humanized IL-15/IL-15Rα-Fc fusion protein that acts as an IL-15 agonist to promote the proliferation and activation of T cells and natural killer (NK) cells; adebrelimab (SHR-1316), a humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) to restore anti-tumor immune responses; and apatinib (BP102), a small molecule tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptor 2 (VEGFR-2) to block tumor angiogenesis. By combining cytokine-driven immune stimulation, immune checkpoint inhibition, and anti-angiogenic effects, the triplet therapy aims to overcome resistance mechanisms and improve clinical outcomes in patients with advanced or metastatic lung cancer.
- Brand names
- Airuika
- Other names
- AdebrelimabApatinibApatinib mesylate
02
Targets
B7-H3EGFR (Epidermal growth factor receptor)CD274 (Programmed cell death protein 1 ligand 1)VEGFR2 (Vascular endothelial growth factor receptor 2)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)
Beyond the preview
Go deeper on FH-006 + adebrelimab + apatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FH-006 + adebrelimab + apatinib.